Literature DB >> 26706779

Irradiation of localized squamous cell carcinoma of the nasal vestibule.

Ben G L Vanneste1, Marta Lopez-Yurda2, I Bing Tan3,4, Alfons J M Balm3,4, Gerben R Borst1, Coen R Rasch5.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the long-term results of primary radiotherapy treatment for squamous cell carcinoma (SCC) of the nasal vestibule.
METHODS: Eighty-one patients were treated with external beam radiotherapy (EBRT) and/or interstitial radiotherapy (IRT) for a primary, localized, Wang classified SCC of the nasal vestibule.
RESULTS: Median follow-up was 38 months. T1 tumors were treated with IRT: we observed 1 local failure (at 13 months) among 48 patients (5-year local control rate of 97%). Most T2 tumors (20 of 26) were treated with EBRT. There were 8 local recurrences among 26 patients (5-year local control rate of 68%). For the T3 tumors (n = 7; all treated with EBRT), we observed local recurrence in 2 patients (5-year local control rate of 53%). The late-term side effects were relatively mild.
CONCLUSION: Local primary radiotherapy (either IRT for T1 or EBRT for T2/3) is an adequate treatment for SCC of the nasal vestibule with little late sequelae.
© 2015 Wiley Periodicals, Inc. Head Neck 38: E1870-E1875, 2016. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  external beam radiotherapy; interstitial radiotherapy; nasal vestibule; squamous cell carcinoma

Mesh:

Year:  2015        PMID: 26706779     DOI: 10.1002/hed.24337

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  2 in total

1.  The presence of aberrant p53 pattern is a negative prognostic predictor in squamous cell carcinoma of the nasal vestibule.

Authors:  Domenic Vital; Gerhard F Huber; David Holzmann; Holger Moch; Kristian Ikenberg
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-07-01       Impact factor: 2.503

2.  Carbon Ion Beam Boost Irradiation in Malignant Tumors of the Nasal Vestibule and the Anterior Nasal Cavity as an Organ-Preserving Therapy.

Authors:  Fabian Eberle; Rita Engenhart-Cabillic; Markus M Schymalla; Christoph Dumke; Ulrike Schötz; Florentine S B Subtil; Kilian-Simon Baumann; Boris A Stuck; Christine Langer; Alexandra D Jensen; Henrik Hauswald; Stefan Lautenschläger
Journal:  Front Oncol       Date:  2022-02-15       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.